ACADIA Pharmaceuticals Statistics
Want to see ACAD full AI Analyst Report?
ACADIA Pharmaceuticals (ACAD) Stock Statistics & Valuation Metrics
Total Valuation
ACADIA Pharmaceuticals has a market cap or net worth of $3.16B. The enterprise value is $2.63B.
- Market Cap
- $3.16B
- Enterprise Value
- $2.63B
Share Statistics
ACADIA Pharmaceuticals has 172,828,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 172,828,980
- Owned by Insiders
- 23.07%
- Owned by Institutions
- 41.20%
Financial Efficiency
ACADIA Pharmaceuticals’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is 8.07%.
- Return on Equity (ROE)
- 0.32
- Return on Assets (ROA)
- 0.25
- Return on Invested Capital (ROIC)
- 8.07%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 1.34M
- Profits Per Employee
- 490.59K
- Employee Count
- 797
- Asset Turnover
- 0.69
- Inventory Turnover
- 2.57
Valuation Ratios
The current PE Ratio of ACADIA Pharmaceuticals is 8.62. ACADIA Pharmaceuticals’s PEG ratio is 0.24.
- PE Ratio
- 8.62
- PS Ratio
- 2.64
- PB Ratio
- 2.28
- Price to FCF
- 28.67
- Price to Operating Cash Flow
- 24.10
- PEG Ratio
- 0.24
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 1.07B and earned 391.00M in profits. Earnings per share was 2.32.
- Revenue
- 1.07B
- Gross Profit
- 982.51M
- Operating Income
- 104.81M
- Pretax Income
- 138.90M
- Net Income
- 391.00M
- EBITDA
- 150.66M
- Earnings Per Share (EPS)
- 2.32
Cash Flow
In the last 12 months, operating cash flow was 131.51M and capital expenditures -20.76M, giving a free cash flow of 110.76M billion.
- Operating Cash Flow
- 131.51M
- Free Cash Flow
- 110.76M
- Free Cash Flow per Share
- 0.64
Dividends & Yields
ACADIA Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.48%
- Earnings Yield
- 11.40%
Stock Price Statistics
- Beta
- 0.98
- 52-Week Price Change
- -22.55%
- 50-Day Moving Average
- 22.84
- 200-Day Moving Average
- 23.50
- Relative Strength Index (RSI)
- 38.92
- Average Volume (3m)
- 2.15M
Important Dates
ACADIA Pharmaceuticals upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
ACADIA Pharmaceuticals as a current ratio of 3.83, with Debt / Equity ratio of 4.25%
- Current Ratio
- 3.83
- Quick Ratio
- 3.71
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.83
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, ACADIA Pharmaceuticals has paid -252.10M in taxes.
- Income Tax
- -252.10M
- Effective Tax Rate
- -1.81
Enterprise Valuation
ACADIA Pharmaceuticals EV to EBITDA ratio is 19.67, with an EV/FCF ratio of 26.47.
- EV to Sales
- 2.44
- EV to EBITDA
- 19.67
- EV to Free Cash Flow
- 26.47
- EV to Operating Cash Flow
- 22.29
Balance Sheet
ACADIA Pharmaceuticals has $976.45M in cash and marketable securities with $71.85M in debt, giving a net cash position of $904.59M billion.
- Cash & Marketable Securities
- $976.45M
- Total Debt
- $71.85M
- Net Cash
- $904.59M
- Net Cash Per Share
- $5.23
- Tangible Book Value Per Share
- $7.26
Margins
Gross margin is 90.48%, with operating margin of 10.17%, and net profit margin of 30.13%.
- Gross Margin
- 90.48%
- Operating Margin
- 10.17%
- Pretax Margin
- 13.08%
- Net Profit Margin
- 30.13%
- EBITDA Margin
- 12.39%
- EBIT Margin
- 11.64%
Analyst Forecast
The average price target for ACADIA Pharmaceuticals is $31.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $31.71
- Price Target Upside
- 72.64% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 14
- Revenue Growth Forecast
- 14.82%
- EPS Growth Forecast
- 36.49%
Scores
- Smart Score
- 8
- AI Score
- 72
